Post-test

Psoriasis Treatment Review
Post Test

A score of 70% must be achieved to receive continuing education credits.

1.

Psoriasis can be a physically devastating disease only.
True
False

2.

Some skin symptoms include
a. Itching
b. Burning
c. Both A & B
d. Neither A & B

3.

Which of the following are biologic agents for Psoriasis therapy:
a. Adalimumab
b. Efalizumab
c. Infliximab
d.All of the above

4.

NB-UVB (Narrow Band) is now the gold standard for therapy.
a. True
b. False

5.

Use of Traditional Systemic Agent Methotrexate includes:
a. Once per week oral therapy
b. Acute and chronic side effects
c. Hepatic toxicity
d. Alcohol Avoidance
e. All of the Above

6.

Use of Cyclosporin includes all of the following except:
a. One a week dosing
b. Quick response
c. Restricted to one year of therapy
d. Renal Toxicity

7.

Biologic Therapy for Psoriasis/Psoriatic Arthritis include:
a. TNF blocking agents
b. T cell agents
c. Both A & B
d. Neither A or B

8

Etanercept is approved for:
a. Double dose first 12 weeks for psoriasis
b. Psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis
c. Both A & B

9

Adalimumab is approved for:
a. Self injected once every other week
b. Only Approved for Psoriasis
c. Very effective for skin lesions
d. Both A & C

10

Efalizumab when used to treat Psoriasis should not be stopped abruptly.
True
False

Activity Evaluation

Please rate this activity on the following scale:
4 - Excellent 3 - Good 2 - Fair 1 - Poor

Due to the content of this activity, I will change my practice patterns by:

	Providing appropriate education to patients
	Provide patients with more information about treatment options
	Identifying patients with a Psoriasis Area & Severity Index (PASI) of less than 75%
	My practice patterns will not change
	Other Specify:

Continuing education implies quality improvement in behavior. As part of our quality improvement process, NAMCP/AAMCN will contact you 6 months from your post test submission to monitor change.